Tilray Inc sell stratec
Summary
This prediction ended on 23.05.19 with a price of €41.32. The SELL prediction by stratec for Tilray Inc performed very well with a performance of -51.89%. stratec has 50% into this predictionTilray, Inc. is a Canadian-based pharmaceutical and cannabis company that is listed on the NASDAQ exchange under the ticker symbol TLRY. The company specializes in the research, cultivation, production, and distribution of medical cannabis products worldwide. Founded in 2013, Tilray has become one of the largest cannabis companies in the world with operations in North America, Europe, and Australia. The company's main areas of focus are medical research and development, consumer brands, as well as global distribution partnerships. As a publicly traded company, Tilray's stock price is subject to market fluctuations and investor sentiment towards the cannabis industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Tilray Inc | -14.105% | -14.105% | -78.620% | - |
| iShares Core DAX® | 0.476% | -0.039% | 13.342% | 17.330% |
| iShares Nasdaq 100 | 1.290% | 0.504% | 40.099% | 50.534% |
| iShares Nikkei 225® | 1.300% | -2.135% | 19.861% | 4.937% |
| iShares S&P 500 | 0.829% | 0.193% | 29.756% | 43.432% |
Comments by stratec for this prediction
In the thread Tilray Inc diskutieren
stratec stimmt der Sell-Einschätzung von tamam zu
stratec stimmt am 20.09.2018 der Sell-Einschätzung von tamam, aber mit dem Kursziel 90$ zu.
Überschrift: The Tilray Bubble Is Bound To Burst
While TLRY does have operations in 29 countries, it is a huge stretch to state that this will lead them to become a global leader (which is what their stock price valuation seems to imply). Most countries arguably are still many years, if not decades, away from legalizing recreational cannabis, meaning that TLRY would only have access to the relatively smaller medical marijuana markets. Furthermore,
logistically speaking, it does not make sense for TLRY to be able to supply cannabis globally from its headquarters in Canada, which is not exactly the ideal location to cultivate cannabis (which is why so many operators have resorted to using greenhouses). If TLRY would need to build production facilities abroad - then I counter with an important question: why wouldn’t a local operator simply beat them to the punch?
These are the two huge assumptions that I do not think investors should be taken as givens. If TLRY was valued much lower, then I could see the global growth thesis as being worthwhile - it’d be the icing on the cake. But as the main reason for owning the stock, the global growth thesis makes for a rather flimsy cake.